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R59022, a diacylglycerol kinase inhibitor, enhances the prostaglandin F2a (PGFZa)-induced diacylglycerol (DAG) synthesis in Swiss 3T3 cells. 
It also potentiates the PGFZa-mediated protein kinase C (PKC)-dependent 80 kDa protein (80K) phosphorylation and initiation of DNA 
replication. R59022 enhances the PGF2a mitogenic response by increasing the rate of entry into the S phase. Insulin does not cause 80K 
phosphorylation, and does not enhance its induction but it potentiates the PGF2a mitogenic response. These results suggest that mitogenically 
triggered fluctuations in DAG content and PKC activity play a pivotal role in controlling the PGF2~-induced DNA synthesis while insulin acts 
via a different mechanism. 
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1. INTRODUCTION 
Mammalian cell proliferation is a highly coordinated 
process [l&3]. Mitogens cause its induction by triggering 
a signalling network leading to the onset of DNA syn- 
thesis and division [l-3]. In Swiss 3T3 cells, prosta- 
glandin F2a! (PGF2a) rapidly increases the inositol 
1,4,5 triphosphate (IP3) and diacylglycerol (DAG) con- 
tent 14471. The latter causes protein kinase C (PKC) 
activation, a PGF2a requirement, to stimulate various 
events. They include, 80K phosphorylation, decreases 
in ‘251-EGF binding affinity properties and the mito- 
genie response [S-IO]. 
Much evidence reveals that the diacylglycerol kinase 
(DGK) enzyme, which converts DAG into phosphatidic 
acid, tightly regulates the cellular DAG content. and 
thereby several PKC-dependent responses [ 11-I 41. 
Whether changes in DGK activity and DAG levels can 
modulate PKC-dependent cell cycle events is of crucial 
importance to understand their role in mitogenesis. 
Here we show that R.59022 [15], a DGK inhibitor, 
potentiates the PGF2a induced-DAG increase as well 
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as the 80K phosphorylation and proIifer~tive response. 
R-59022 enhances the PGF2a induced entry into the S 
phase without altering the Gl phase length. Insulin, 
which does not cause PKC activation, potentiates 
PGF2ff-induced mitogenesis. These results indicate that 
DAG content and PKC activity fluctuations triggered 
by PGF2a play a crucial role controlling the rate of 
initiation of DNA replication. We also conclude that 
insulin enhances this effect via a separate signal(s). 
2. MATERIALS AND METHODS 
7. I. Cell culture. DNA syuhesis and SOK phosphorylution ssq 
Swiss mouse 3T3 cells [I61 culture, assay of DNA synthesis by 
autoradiography and calculation of the rate constant K value for entry 
into the S phase were as previously reported [ 1, IO]. 80K phosphoryla- 
tion culture conditions, labeling, determination procedures and den- 
sitometric analysis were as described [8,17]. 
2.2. 1.2 Diucylglycerol wntent 
Cells were plated on 100 mm Petri dishes similar to the DNA 
synthesis assay [4]. After four days, cells received IO ml of fresh 
medium with 25 PCi [ZH]glycerol and 4 days later they become confu- 
ent and resting (41. Upon isolation, 103 cpm [“‘Clcholesteryl oleate was 
added to lysates for recovery estimation [18]. Chromatography of 
lipids and detection were as described before [4, IS], 
2.3. Matrrirrls 
R59022 was a gift from Dr. D. Chaffay de Courcelles. Jansen Life 
Science. Chemicals were obtained from Sigma Chemical Company. 
[methj&‘H]Thymidine (I 8 Ci/mmol), ‘?Pt (8,500 Cilmmol) and 
[“‘Clcholesteryl oleate (59 Ci/mmol) were purchased from New Eng- 
land Nuclear. [“HjGlycerol (15 Ci/mmol) was from American Radiola- 
beled Chemicals. 
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MINUTES 
Fig. I. Time-dependent DAG increase upon PGFZa or PGF2a- 
R59022 addition. R59022 (8 PM) was added I h prior to PGF2a. (0), 
control: (A), R59022 (8 FM): (0). PGF2a (300 ng/ml) and (A). PGF2a 
plus R59022. 1,3-Diacylglycerol and triacylglycerol content did not 
vary under these conditions. The inset shows the effect of R59022 
upon EGF (20 @ml) induction after 5 min. Additions were as follows: 
C, control; R, R59022; E, EGF; R+E; P, PGF2a. The assay was 
carried out as described in section 2. 
3. RESULTS 
3.1. R59022 enhances PGF2a-induced DAG content 
The R59022 potentiation of the PGF~~-dependent 
DAG increase at various times upon mitogenic induc- 
tion of confluent resting Swiss 3T3 cells is shown in Fig. 
1. PGF2a added at 300 &ml caused a rapid maximal 
raise (two-fold) in DAG content within 5 min of stimu- 
lation. Thereafter DAG levels decline to or even below 
the unstimulated level (Fig. 1). R59022 by itself has little 
effect on DAG levels. However it enhances the rate at 
which PGF2rr induces DAG content increase, reaching 
a value that is 1.4-fold higher than with PGF2a alone 
(Fig. 1). Neither EGF alone [4] nor EGF plus R59022 
caused DAG increases (Fig. 1 inset). 
3.2. R.59022 potentiates 80Kphosphorylation 
PGF2a (30 or 300 rig/ml) stimulation for 10 min trig- 
gers a PKC-dependent 80K phosphorylation to a differ- 
ent extent (Fig. 2A). R59022 (8 PM) added by itself has 
no effect, but it increases the PGF2a-induced 80K phos- 
phorylation almost in a similar fashion for both PGF2cz 
concentrations (Fig. 2B). TPA, 12-U-tetradecanoyl- 
phorbol-13-acetate, a PKC activator, renders maximal 
effect (Fig. 2A,B). In contrast, insulin neither causes 
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Fig. 2. (A) R59022 potentiation of 80K phosphorylation induced by two PGF2a concentrations. Additions were for 10min as indicated: (1) R59022; 
(2) PGF2a 30 ngiml; (3) PGF2a 30 ngiml plus R59022; (4) PGFZct 300 q/ml; (5) PGF2a 300 ng/ml plus R59022: (6) control; and (7) TPA. 
(S) Densitometric analysis. PGF2a 300 ngiml represents the 100% value. R59022 was added as in Fig. 1. 
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Fig. 3. (A) PGF2a (300 &ml) and insulin (50 nglml) differential 
action on 80K phosphorylation. Additions were as indicated: (1) con- 
trol: (2) PGF2a: (3) PGF2a plus insulin; and (4) insulin. (B) Densito- 
metric quantification. Assay conditions were as in Fig. 2. 
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80K phosphorylation nor potentiates this PGF2cr- 
induced event (Fig. 3). 
3.3. R59022 entrances PGF2a mi~ogenic response 
The R59022 potentiation of PGF2a-induced mito- 
genesis is shown in Fig. 4A. R59022 (l-20 ,LLM) by itself 
has no effect but with PGF2a at 30 or 300 ng/ml causes 
a dose-dependent labeling index increase reaching a 
maximum at 10 PM (Fig. 4A). R59022 also exerts syn- 
ergistic action upon PGF2a induction by lowering the 
PGF2cx dose requirement (Fig. 4B). Insulin (10m9 M), 
which in these cells is not mitogenic [l,lO], further in- 
creases the PGF2a- or PGF2a-R59022-induced DNA 
synthesis (Fig. 4C. The R59022 action is exerted by 
enhancing the K value for entry into the S phase without 
altering the Gl length regardless of the PGF2a concen- 
tration (Fig. 5). In addition, R59022 does not change 
the PGF2a--insulin induced DNA synthesis initiation 
kinetics (Fig. 5). 
4. DISCUSSION 
Cumulative findings indicate that in mammalian cells 
the DGK enzyme is a key regulator of the DAG content 
119,201. Hence, DGK exerts control upon the PKC- 
activation threshold which is reflected on PKC-depend- 
ent events [21,22]. R.59022-DGK inhibition-induced 
platelets or neutrophils cause potentiation of PKC-con- 
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Fig. 4. (A) R59022 potent&ion of PGFZa mitogenic response. (o), R59022; (0), R59022 plus PGF2a 30 @ml; (A), RS9022 plus PGF2a 300 nglml. 
(B) PGF2a dose-response minus (n) or (A) plus R59022 at 8 ,uM. (C) Effect of insulin (50 &ml) on the PGF2a mitogenic response minus or plus 
8 ,uM R59022. (a), PGF2cc; (o), PGF2a plus insulin; and (w), PGF2a plus insulin and R59022. DNA synthesis was assayed as indicated in 
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Fig. 5. Kinetics of entry into the S phase triggered by PGF2a minus 
or plus R59022 (8 PM) without or with insulin (50 ng/ml). Additions 
were as follows: (v), Control (K = 0.05); (A), insulin plus R59022 (K 
= 0.07); (o), PGFZct (30 ngiml) (iu = 0.80); (o), PGF2a (30 ng/ml) plus 
R59022 (K = I .80); (v), PGF2a (30 &ml) plus insulin (K = 5.67); (+), 
PGF2a (30 ng/ml) plus R59022 and insulin (K = 5.69); (zI), PGF2a 
(300 ng/ml) (K = 2.11); (D), PGFZcr (300 ng/ml) plus R59022 (K = 
3.21): fo), PGF2n (300 nglml) plus insulin (K = 5.71); (n), PGF2c( (300 
ngiml) plus R59022 and insulin (K = 5.70); (x), serum (K = 23.0). ir; 
values are given in IO-’ h. In all cases the duration of Cl was 14 h. 
Labeling procedures were as in Fig. 4. 
trolled processes [1418]. Also, in bombesin-stimulated 
Swiss 3T3 cells, R59022 enhances some early PKC-me- 
diated events and mitogenesis [17]. Yet, it is not clear 
whether R59022 causes further bombesin-induced 
DAG-content increases [23] and its occurrence in the 
cell cycle. 
Here we show that in Swiss 3T3 cells, R59022-DGK 
inhibition reduces the PGF2a-DAG generation time 
and transiently increases its content. R59022 also en- 
hances the PGF2ol-triggered PKC-dependent 8OK 
phosphorylation and mitogenesis. PKC down-modula- 
tion prevents PGF2a or PGF2a-R59022 from causing 
the latter events, indicating their PKC requirement (not 
shown). Our results also suggest that PGF2a triggers 
both DAG-content increases and possibly DGK activ- 
ity. Plateled-derived growth factor, in these cells, also 
stimulates both processes [24]. The cause of the inability 
of R59022 to maintain higher PGFZa-induced DAG 
levels is unknown, but likely to be a consequence of 
alternative DAG metabolic conversion that occurs in 
mitogenically induced Swiss 3T3 cells [25]. 
Of relevance is the fact that R59022 enhances the 
PGF2a-induced DNA synthesis by increasing the rate 
of entry into the S phase without altering the length of 
Cl. This implies that either PGF2a- or PGF2a- 
R59022-triggered DAG content and PKC activity in- 
creases are crucial transient events to determine Gl 
progression and exert control upon processes regulating 
the onset of DNA replication [lo]. In contrast, insulin, 
which in these cells neither raises DAG content [4] nor 
causes 80K phosphorylation or enhances the effect of 
PGF2a on both events, only increased the PGF2a-in- 
duced rate of entry into the S phase. 
These findings also indicate that cell cycle control is 
exerted by two independent signalling mechanisms 
which, acting in concert, modulate the initiation of 
DNA replication. PGF2a triggers a DAG-PKC-de- 
pendent cascade of events which is causative of mito- 
genesis. Nevertheless we have shown that PKC activa- 
tion cannot solely account for the PGF2a-triggered pro- 
iiferative response but it requires complementary sig- 
nal(s) [lo]. In contrast, insulin synergistically enhances 
it by a separate amplifying mechanism. The latter is not 
exerted in early [8,9], but in late PK~-downstream-de- 
pendent events involving protein synthesis [10,26-281. 
To unravel crucial time-dependent cell cycle events that 
occur upon transient DAG-content change and PKC 
activation is our present research endeavour. 
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